Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways for tissue growth, repair, and regeneration. The company operates in a single segment (developmental biology products) and relies heavily on strategic collaborations (e.g., Genentech, Wyeth, Procter & Gamble) for funding and commercialization. The company has never been profitable and maintains an accumulated deficit of approximately $688 million.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|
| Gross Revenues | $5,969,605 | $5,306,379 |
| Net Revenues | $4,597,314 | $427,877 |
| Net Loss | $(7,973,189) | $(10,239,248) |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $(0.21) |
| Cash and Cash Equivalents (End of Period) | $23,809,997 | $19,136,568 |
| Marketable Securities | $17,999,916 | $21,899,024 |
| Total Current Assets | $43,243,940 | $45,892,153 |
| Total Current Liabilities | $10,308,947 | $9,881,078 |
| Long-Term Debt Obligations | $1,350,000 | $1,966,667 |
| Net Cash Used in Operating Activities | $(1,826,317) | $(3,715,159) |
Material Changes vs. Prior Period
- Revenue Surge: Net revenues increased by approximately 974% year-over-year (from $428k to $4.6M). This was primarily driven by a $3.5 million decrease in "contra-revenues" (cost reimbursements to Genentech) rather than a massive increase in gross revenue, which only grew 12%.
- Improved Loss Position: Net loss decreased by approximately 22% year-over-year, largely due to the reduction in contra-revenue charges and lower operating cash burn.
- Stock-Based Compensation: The adoption of SFAS 123(R) on January 1, 2006, resulted in a significant increase in recognized stock-based compensation expense ($1.88M for the six months ended June 30, 2006, compared to $27.6k in the prior year).
- Debt Reduction: The company converted a $2.6 million convertible note payable to Becton Dickinson into common stock, eliminating that specific debt obligation.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Liquidity: Management believes existing capital resources, combined with expected collaboration payments, will fund operations into 2008. Additional financing may be required thereafter.
- Strategic Shift: The company announced a strategic focus on later-stage drug development and de-emphasis of early-stage discovery. Consequently, the Spinal Muscular Atrophy (SMA) discovery program is expected to terminate in the second half of 2006.
- Genentech Collaboration: Enrollment in the Phase I clinical trial for basal cell carcinoma was halted in July 2006 due to insufficient clinical activity and formulation issues. The companies are evaluating next steps, which could include reformulation or termination.
Risks and Contingencies
- Financial Restatement: The company restated financial results for 2003, 2004, and 2005 due to accounting errors regarding revenue recognition (specifically $7.5M in Genentech payments) and R&D expenses. This carries a risk of securities litigation.
- Lease Obligations: A subtenant for the company's facility may default. The company has accrued $457,000 for potential lease losses if the space cannot be re-sublet.
- Legal Disputes: The company is involved in litigation with Micromet (now CancerVax) regarding unpaid milestone payments totaling approximately EUR 2 million. Collection is not currently considered reasonably assured.
- Key Personnel: Dr. Lee Rubin, Executive Vice President and Chief Scientific Officer, resigned in July 2006. Dr. Joseph Davie (Board Member) serves as interim CSO.
Investor Verification Checklist
- Genentech Trial Status: Verify the outcome of the decision-making process regarding the halted basal cell carcinoma Phase I trial and the potential financial impact of termination vs. reformulation.
- Restatement Implications: Monitor for any ongoing or new securities litigation stemming from the 2003-2005 financial restatement.
- Liquidity Runway: Confirm the company's ability to meet the 2008 funding horizon, specifically the timing of expected payments from Genentech, Wyeth, and Procter & Gamble.
- Lease Risk: Assess the financial impact if the subtenant at 61 Moulton Street defaults, potentially triggering the $457,000 accrued liability and additional costs.
- Stock-Based Compensation: Review the impact of the new SFAS 123(R) accounting standard on future quarterly expenses, estimated at $3.75M-$4.25M for the full year 2006.